Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial
11 p.
- Autores:
-
Lopez-Jaramillo, Patricio
Dagenais, Gilles
Jung, Hyejung
Lonn, Eva
Bogaty, Peter M.
Dehghan, Mahshid
Held, Claes
Avezum, Alvaro
Petr, Jansky
Keltai, Matyas
Lawrence A., Leiter
Toff, William D.
Bosch, Jackie
Yusuf, Salim
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2018
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/3168
- Acceso en línea:
- https://repositorio.udes.edu.co/handle/001/3168
- Palabra clave:
- Antihypertensive agent
Statin
- Rights
- openAccess
- License
- Derechos Reservados - Universidad de Santander, 2018
| id |
RUDES2_ff434dff6adf31c093f048adb6c5e7a0 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/3168 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| title |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| spellingShingle |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial Antihypertensive agent Statin |
| title_short |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| title_full |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| title_fullStr |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| title_full_unstemmed |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| title_sort |
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial |
| dc.creator.fl_str_mv |
Lopez-Jaramillo, Patricio Dagenais, Gilles Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Petr, Jansky Keltai, Matyas Lawrence A., Leiter Toff, William D. Bosch, Jackie Yusuf, Salim |
| dc.contributor.author.spa.fl_str_mv |
Lopez-Jaramillo, Patricio Dagenais, Gilles Jung, Hyejung Lonn, Eva Bogaty, Peter M. Dehghan, Mahshid Held, Claes Avezum, Alvaro Petr, Jansky Keltai, Matyas Lawrence A., Leiter Toff, William D. Bosch, Jackie Yusuf, Salim |
| dc.subject.proposal.eng.fl_str_mv |
Antihypertensive agent Statin |
| topic |
Antihypertensive agent Statin |
| description |
11 p. |
| publishDate |
2018 |
| dc.date.issued.spa.fl_str_mv |
2018 |
| dc.date.accessioned.spa.fl_str_mv |
2019-06-20T13:35:30Z |
| dc.date.available.spa.fl_str_mv |
2019-06-20T13:35:30Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.spa.fl_str_mv |
10.1161/JAHA.118.008918 |
| dc.identifier.issn.spa.fl_str_mv |
2047-9980 |
| dc.identifier.uri.spa.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/3168 |
| identifier_str_mv |
10.1161/JAHA.118.008918 2047-9980 |
| url |
https://repositorio.udes.edu.co/handle/001/3168 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.eng.fl_str_mv |
Journal of the American Heart Association |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Santander, 2018 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Derechos Reservados - Universidad de Santander, 2018 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.source.eng.fl_str_mv |
https://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.008918 |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/1404bcbf-cbfc-4666-845c-68eb85a5985e/download https://repositorio.udes.edu.co/bitstreams/5ac9fedf-0deb-48c5-9662-1e2e70c2d334/download https://repositorio.udes.edu.co/bitstreams/0b5a745c-61e5-4536-9b6d-74af141a1686/download https://repositorio.udes.edu.co/bitstreams/d716aa36-8066-4503-9c42-7174216f10e8/download https://repositorio.udes.edu.co/bitstreams/fd0c7cc8-b099-43d8-9e96-aadf57d7564f/download https://repositorio.udes.edu.co/bitstreams/55dc60be-e0c8-4ce4-a594-296744019a33/download |
| bitstream.checksum.fl_str_mv |
1425ed1c1464c268495feb25796c30e8 f43a962dec9b7542cfc6aae0c49530b7 38d94cf55aa1bf2dac1a736ac45c881c fa43e57d0448641f1c3280f2705f04b7 bfb807988aaed3c396611fc3202b41fb 8f1d3ca7e8fa3d8ad8529223d7109475 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814159021283737600 |
| spelling |
Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Jung, Hyejung50f4ceae-59e5-4f12-9788-b713f56de3be-1Lonn, Eva7a977a4b-14e3-44cc-8057-933d424aaa9b-1Bogaty, Peter M.01181416-cd18-4fdc-b6d1-5747187c27d7-1Dehghan, Mahshid24c90dd8-52a1-41e0-8c9a-52ee9ce29532-1Held, Claes76b69ce8-c468-49c5-8d48-95a823d8b565-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Petr, Janskye1bb758f-bf90-4911-b8ca-878f0f7a0845-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Lawrence A., Leiterbc66c731-2a62-4d44-8812-05a26b206a5d-1Toff, William D.97acb6df-c33b-45ad-b772-c52ac4aa7281-1Bosch, Jackie503f2202-0dda-463c-acc9-f5888e895278-1Yusuf, Salim06a836b5-f5e3-41d9-a516-9cc46e5d7948-12019-06-20T13:35:30Z2019-06-20T13:35:30Z201811 p.Background-—It is not clear whether the effects of lipid-lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE-3 (Heart Outcomes Prevention Evaluation) trial. Methods and Results-—In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (CVD) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow-up was 5.6 years. The outcome was a composite of CVD events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of CVD compared with those with fewer factors (HR: 0.85; 95% CI, 0.73–1.00). Rosuvastatin reduced CVD events in participants with ≥2 healthy lifestyle factors (HR: 0.74; 95% CI, 0.62–0.90) and in participants with <2 factors (HR: 0.79; 95% CI, 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors: HR: 0.74; 95% CI, 0.57–0.97; <2 factors: HR: 0.61; 95% CI, 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce CVD only in participants with <2 healthy lifestyle factors (HR: 0.78; 95% CI, 0.61–1.00). Conclusions-—Healthy lifestyles are associated with lower CVD. Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles.application/pdf10.1161/JAHA.118.0089182047-9980https://repositorio.udes.edu.co/handle/001/3168engJournal of the American Heart AssociationDerechos Reservados - Universidad de Santander, 2018info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.008918Antihypertensive agentStatinEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85PublicationTHUMBNAILEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention. An analysis of the HOPE-3 trial.pdf.jpgEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention. An analysis of the HOPE-3 trial.pdf.jpgGenerated Thumbnailimage/jpeg1742https://repositorio.udes.edu.co/bitstreams/1404bcbf-cbfc-4666-845c-68eb85a5985e/download1425ed1c1464c268495feb25796c30e8MD54Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdf.jpgEffects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdf.jpgGenerated Thumbnailimage/jpeg16874https://repositorio.udes.edu.co/bitstreams/5ac9fedf-0deb-48c5-9662-1e2e70c2d334/downloadf43a962dec9b7542cfc6aae0c49530b7MD57LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/0b5a745c-61e5-4536-9b6d-74af141a1686/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALEffects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdfArtículo Principalapplication/pdf356457https://repositorio.udes.edu.co/bitstreams/d716aa36-8066-4503-9c42-7174216f10e8/downloadfa43e57d0448641f1c3280f2705f04b7MD55TEXTEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention. An analysis of the HOPE-3 trial.pdf.txtEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention. An analysis of the HOPE-3 trial.pdf.txtExtracted texttext/plain45172https://repositorio.udes.edu.co/bitstreams/fd0c7cc8-b099-43d8-9e96-aadf57d7564f/downloadbfb807988aaed3c396611fc3202b41fbMD53Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdf.txtEffects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdf.txtExtracted texttext/plain46188https://repositorio.udes.edu.co/bitstreams/55dc60be-e0c8-4ce4-a594-296744019a33/download8f1d3ca7e8fa3d8ad8529223d7109475MD56001/3168oai:repositorio.udes.edu.co:001/31682023-10-10 09:17:24.985https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Universidad de Santander, 2018https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |